Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enkephalin SCHEMBL631959 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL11399380 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL16189980 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30857 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL25236888 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30400052 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL29458101 | 0.98 | OPRD1 (0.72) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29355873 | 0.98 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL8580265 | 0.95 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| SCHEMBL8077732 | 0.94 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | claimed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | claimed |
| US-12399186-B2 | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction | SPHINGOTEC GMBH (DE) | 2025-08-26 | — | — | US | claimed |
| EP-4603151-A1 | STABLE COSMETIC COMPOSITION, METHODS AND USES THEREOF | Solfarcos Soluções Farmaceuticas e Cosmeticas Lda (PT) | 2025-08-20 | — | — | EP | claimed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | claimed |
| CN-113421620-B | Based on UPLC-Q-TOF/MSEMethod for carrying out fuzzy recognition on bioactive components with different effects of traditional Chinese medicine by BP neural network correlation analysis of integration effect | 陕西中医药大学 | 2025-04-29 | — | — | CN | claimed |
| CN-119403786-A | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes | 德罗普尼尔生物有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-12208118-B2 | Pharmaceutical compositions for delivery of peptide | ANYA BIOPHARM INC. (CN) | 2025-01-28 | — | — | US | claimed |
| EP-4486366-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2025-01-08 | — | — | EP | claimed |
| WO-2023285412-A1 | IMPROVED SUBSTANCE QUANTIFICATION IN COMPLEX MIXTURES | ISA PHARMACEUTICALS B.V. (NL) | 2023-01-19 | — | — | WO | claimed |
| US-20220347184-A1 | SKIN-PENETRATING FORMULATION OF TAUROLIDINE | CORMEDIX INC (US) | 2022-11-03 | — | — | US | claimed |
| US-20220288111-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC. (CN) | 2022-09-15 | — | — | US | claimed |
| CN-111812246-B | Method for tracking blood-entering components of five-flavor warmth-dredging and arthralgia-removing capsule and targeting quality marker | 安徽中医药大学第一附属医院(安徽省中医院) | 2022-06-10 | — | — | CN | claimed |
| CN-114414673-A | Method for identifying vegetable oil types | 哈尔滨医科大学 | 2022-04-29 | — | — | CN | claimed |
| CN-114414671-A | Research method for metabolic pathway of diabetes differential metabolites by using coreopsis bicolor | 天津中医药大学 | 2022-04-29 | — | — | CN | claimed |
| CN-114235979-A | Marine microorganism lipid ion mobility mass spectrometry method and application | 南方科技大学 | 2022-03-25 | — | — | CN | claimed |
| CN-114137226-A | Marker for early diagnosis of cerebral infarction, screening method and application thereof, and construction method and application of model for early diagnosis of cerebral infarction | 首都师范大学 | 2022-03-04 | — | — | CN | claimed |
| CN-114062473-A | Method for evaluating storage quality of dried sea cucumbers based on iKnife evaporation ionization mass spectrometry | 浙江工商大学 | 2022-02-18 | — | — | CN | claimed |
| CN-113968902-A | Leucine-enkephalin analogue and preparation method and application thereof | 兰州大学 | 2022-01-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | OPRD1 3942/4885OPRM1 3885/4885OPRK1 4105/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | OPRD1 1918/4885OPRM1 865/4885OPRK1 3676/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | OPRD1 722/4885OPRM1 744/4885OPRK1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.